Location · Denver, CO
Clinical trials in Denver, CO
493 recruiting studies have a site in the Denver area, and 165 of them accept healthy volunteers. The area includes Aurora, Lakewood, Englewood, Littleton, Centennial, Lone Tree and nearby cities.
493 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Eli Lilly and Company
- Location
- Aurora, CO + 3 other US sites
- Eligibility basics
- Ages 1–35
- RecruitingPhase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals
- Location
- Aurora, CO + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Birmingham, AL + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Cullman, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company
- Location
- Phoenix, AZ + 38 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Eli Lilly and Company
- Location
- Oxnard, CA + 9 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2/Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
- Location
- Birmingham, AL + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Phoenix, AZ + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- Recruiting
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Uromedica
- Location
- Denver, CO + 3 other US sites
- Eligibility basics
- Ages 22+ · Women only
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Loma Linda, CA + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Huntsville, AL + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
- Location
- Aurora, CO + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Birmingham, AL + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Phoenix, AZ + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics, Inc.
- Location
- Lancaster, CA + 30 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Hoffmann-La Roche
- Location
- Orange, CA + 9 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Little Rock, AR + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Anagram Therapeutics, Inc.
- Location
- Long Beach, CA + 19 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Saraland, AL + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Amgen
- Location
- Scottsdale, AZ + 12 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
GlaxoSmithKline
- Location
- Sheffield, AL + 50 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Chino, CA + 23 other US sites
- Eligibility basics
- Ages 18–65